ObjectiveTo explore a better method to obtain human temporomandibular joint synovial type A cells， and lay a methodological foundation for the further study of type A cells.MethodsSynovial cells are cultured with tissue block method， traditional enzyme digestion method and improved enzyme digestion method respectively. The growth of synovial cells is observed at 3， 7， 2 week and 4 week of culture， and the first passage time is recorded. The expression of CD68 and cathepsin S in lining cells is detected by immunohistochemistry to determine the phagocytic function of type A cells.ResultsAbout 7 days after inoculation with synovial tissue block method， some cells are free around the tissue block， and the growth of synovial cells is close to 80% of the fusion density after about 4 week， which can be used for the first cell passage. The cells adhere slowly with traditional enzyme digestion method， and the formation of some cell clusters can be observed only after 4 week， and grow radially around， and the first passage can be made after about 6 week. Three days after inoculation with the modified enzyme digestion method， we observe under the light microscope that part of the single cells adhere to the wall. There are some small tissue blocks or cell blocks that are not fully digested by collagenase and can be ground through the filter screen. After adhering to the wall， they proliferate rapidly to the surrounding area. After about 2 week， they can be subcultured firstly. After 3 week， the number of cells subcultured is the same as that of the first cell subcultured after 4 week of the tissue block method. Immunohistochemical examination has shown that CD68 is positive， and the cells are located near the articular cavity， while cathepsin S is not positive.ConclusionCompared with tissue block method and traditional enzyme digestion method， the modified enzyme digestion method can shorten the time of primary cell culture on the basis of obtaining the same cell quantity. Type A cells are still alive during the passage of the modified enzyme digestion method， which can lay a foundation for the purification and separation of type A cells in the later stage. The macrophage marker cathepsin S is not expressed on type A cells， suggesting that type A cells are different from macrophages due to the effect of local environment in vivo.
ObjectiveTo investigate the effect of signal transcription and activation factor 3 （STAT3） inhibitor WP1066 on the proliferation of human airway BEAS-2B cells and explore the potential molecular mechanism of WP1066 in the treatment of bronchial asthma.MethodsAfter pretreatment with WP1066， the proliferation of BEAS-2B cells was determined by MTT assay. The level of STAT3 phosphorylation and its downstream target Cyclin D1 were measured by Western Blot.ResultsWP1066 inhibited the proliferation of BEAS-2B cells in a concentration-dependent manner. WP1066 did not reduce the total STAT3 protein level， but inhibited the phosphorylation of STAT3 and down-regulated the expression of Cyclin D1 protein.ConclusionWP1066 can inhibit the proliferation of human airway epithelial cells by blocking the STAT3 signaling pathway.
ObjectiveA Meta-analysis was conducted to systematically analyze the efficacy and safety of apatinib combined with SOX regime（oxaliplatin+tegafur）in patients with advanced gastric cancer.MethodsPubMed， Embase， Cochrane Library， ClinicalTrials.gov， WANFANG DATA and CNKI were searched for randomized controlled trials studying the efficacy and safety of apatinib combined with SOX in the treatment of advanced gastric cancer patients. Data were extracted from the included literature， and the main outcome indicators were as follows： objective response rate （ORR）， disease control rate （DCR）； secondary outcome indicators： partial response rate （PRR） and safety related indicators， including hypertension， proteinuria， hand-foot syndrome， diarrhea， oral mucositis， fatigue， leukopenia， thrombocytopenia. All statistical analyses were performed using meta package for R version 4.0.3.Results1699 articles were retrieved and 28 articles with a total of 2110 subjects were ultimately included. Compared with SOX regimen， apatinib combined with SOX regimen improved DCR （OR= 3.90， 95%CI： 3.15 - 4.83，P< 0.001） and ORR （OR= 2.73， 95%CI： 2.26 - 3.31，P< 0.001）， PRR （OR= 2.33， 95%CI： 1.94 - 2.81，P< 0.001）， but increased hypertension （OR= 2.47， 95%CI： 1.26-4.83，P= 0.008）， proteinuria （OR= 2.16， 95%CI： 1.46-3.21，P< 0.001）， hand-foot syndrome （OR= 2.19， 95%CI： 1.44 - 3.32，P< 0.001）. The difference was statistically significant.ConclusionThe results of this meta-analysis showed that apatinib combined with SOX regime was effective in the treatment of advanced gastric cancer with relatively mild adverse events， which is expected to be applied in clinical practice.
ObjectiveTo analyze the efficacy of elemene combined with Endostatin （recombinant human endostatin） and cisplatin in the treatment of malignant pleural effusion in non-small cell lung cancer.Methods98 patients with non-small cell lung cancer and malignant pleural effusion who were treated in Liaocheng Second People’s Hospital from October 2020 to October 2023 were included. They were divided into groups with computer random number method. There were 49 cases in the research group and the control group respectively， all of whom underwent Endo and Orthopedic Surgery. For platinum treatment， the research team added elemene to complete the short-term efficacy evaluation. The patients' serum tumor markers and T lymphocyte subpopulations were measured before/after treatment， their physical status and quality of life were evaluated， and the adverse reactions of the patients' chest pain， fever， and white blood cells were counted.ResultsComparing the response rate， the study group was 73.47%， which was significantly higher than the 51.02% in the control group （P< 0.05）； after treatment， the serum squamous cell carcinoma antigen （SCC） and carcinoembryonic antigen （carcinoembryonic antigen） in the study group were antigen， CEA） was （6.98 ± 0.71） mg/L，（7.05 ± 0.73） mg/L， and the study group was significantly lower than the （8.06 ± 0.88） mg/L，（8.45 ± 0.91） mg/L of the control group （P<0.05）； after treatment the CD4+and CD4+/CD8+ratios in the study group were （44.97 ± 4.87）% and （2.24 ± 0.22）， which were higher than those in the control group （41.63 ± 4.69）% and （1.80 ± 0.19）. The CD8+ratio was （20.05 ± 2.17）%， which was lower than the （23.12 ± 2.69）% in the control group （P< 0.05 ）； after treatment， the Eastern Cooperative Oncology Group （ECOG） score of the study group was （1.47 ± 0.15） points， which was lower than the （1.83 ± 0.19） points of the control group， and the score of the Karnofsky Function Status Score （KPS） was （80.93 ± 8.14） points， which was higher than the （76.14 ± 7.91） points in the control group （P< 0.05）； the total incidence of adverse reactions such as chest pain， leukopenia， and thrombocytopenia in the study group was 32.65%， which was not significantly different from the 26.53% in the control group （P> 0.05）.ConclusionElemene combined with Endol and Cisplatin has a good effect in the treatment of malignant pleural effusion of non-small cell lung cancer. It can reduce the level of tumor markers in patients and restore the balance of T lymphocyte subpopulations， which is beneficial to improving the quality of life of patients.
ObjectiveTo understand the detection rate and prevalence of hyperuricemia in the physical examination population and to analyze the factors affecting the prevalence of hyperuricemia， so as to provide a basis for its scientific prevention and control.MethodsIn this study， the 2021—2023 physical examination population of a public hospital in Anhui Province was selected as the study subjects， and their demographic characteristics and serum uric acid indicators were collected， and the detection rate of hyperuricemia and the possible risk factors of the physical examination population were analyzed by theχ2test and logistic regression.ResultsA total of 180 397 subjects were included in the study， of which 94 575 were male （52.42%） and 85 822 were female （47.58%）. The overall detection rate of hyperuricemia was 21.34%， of which the detection rate of male was 32.20% and the detection rate of female was 11.56% （P< 0.01）. The detection rates of male， overweight and obese， young people， and hypertension were higher than those of other groups. The detection rate of male， overweight and obesity， youth， and hypertension was higher than that of other populations （P< 0.01）. There was a positive correlation between male， BMI， youth， hypertension， creatinine and hemoglobin and hyperuricemia， and a negative correlation between glomerular filtration rate， fasting glucose and hyperuricemia.ConclusionThe detection and prevalence of hyperuricemia is not optimistic， and it is necessary to further popularize the knowledge of hyperuricemia， advocate health education， and cultivate a healthy lifestyle to achieve the prevention and treatment of hyperuricemia.
ObjectiveTo investigate the relationship between dietary patterns and hyperuricemia （HUA） in American adults.MethodsThis study was based on population data of the National Health and Nutrition Examination Survey （NHANES） 2007—2018 year. According to the inclusion and exclusion criteria， 25，526 US adult residents were finally included in this study. Principal component analysis was used to extract the dietary patterns of the survey respondents. Restricted cubic spline （RCS） regression model was applied to detect the possible linear or non-linear dependency of the relationship between dietary patterns and the prevalence risk of HUA with 3 knots adjusting for all confounders. The association between different dietary patterns and the risk of prevalence of hyperuricemia was analyzed by multifactorial logistic regression after quartiles of dietary pattern factor scores， with the lowest quartile as the reference. The covariates in the logistic regression model include age， gender， race， education， family income poverty rate， BMI， smoking， drinking， physical activity， dietary supplement use， Healthy Eating Index， total energy， and high-purine food intake.ResultsThree patterns were extracted by principal component analysis. These are labeled as fat-processed grain-cheese-added sugar （FPCS）， oil-vegetables-nuts-whole grains （OVNW） pattern and oil-white potatoes-drink-seafood （OPDS） pattern. RCS analysis showed that FPCS pattern score was linearly related to the risk of HUA （P-linear < 0.001）， and the higher the FPCS pattern score， the lower the prevalence of HUA. The OVNW pattern score was linearly related to the risk of HUA （P-linear < 0.001） and the higher the OVNW pattern score， the lower the prevalence of HUA. There was a linear relationship between the OPDS pattern score and the risk of HUA （P-linear < 0.001） and the higher the OPDS pattern score， the higher the prevalence of HUA. In logistic regression， FPCS and OVNW patterns were negatively associated with prevalence risk of hyperuricemia （Q4：OR= 0.74， 95%CI0.62－0.87） and （Q4：OR= 0.76，95%CI0.66－0.87） respectively. However， OPDS pattern was positively associated with prevalence risk of hyperuricemia （Q4：OR= 1.54，95%CI1.41－1.70）.ConclusionFPCS and OVNW patterns were associated with decreased prevalence risk of hyperuricemia in the Adults of United States， whereas OPDS patterns were associated with increased prevalence risk of hyperuricemia.
ObjectiveTo broaden the channels through which factors influencing healthcare choices are considered， including social factors， in order to provide insights for the allocation of medical resources， expedited development of tiered healthcare， and upgrades to public healthcare networks.MethodsEmploying OLS regression models， a comprehensive analysis of the impact of social trust， individual， family， and regional factors on healthcare choices was conducted. Heterogeneity analysis was performed with a propensity score matching （PSM） model.ResultsA negative correlation was observed between the trust level of doctors and patients and healthcare choices， with higher individual trust in doctors leading to a greater inclination toward seeking healthcare at primary care facilities.ConclusionHigher levels of trust between doctors and patients can guide the downward distribution of medical resources. Policy support and strengthened medical collaboration can accelerate the development of primary healthcare.
Lung cancer is one of the malignant tumors with the fastest increase in morbidity and mortality and the greatest threat to human life worldwide. Patients diagnosed with lung cancer usually receive a variety of treatments， including surgery， chemotherapy and/or radiation therapy， immunotherapy， and targeted therapy； However， the five-year survival rate for lung cancer remains low， especially when the cancer has reached an advanced stage or distant metastasis has occurred. Therefore， more effective and novel technologies must be developed to solve this problem. Inducer application of immunogenic cell death （ICD） has been proved to enhance immunity in patients receiving various types of therapy. The term ICD refers to a type of cell death that triggers an immune response to dead cell antigens， especially antigens derived from cancer cells. It was originally proposed about the effects of anti-cancer chemotherapy with traditional cytotoxic drugs. The purpose of this study is to review and discuss the role and mechanism of ICD as a promising combination immunotherapy for lung cancer.
As a significant challenge to women's health globally， the research of breast cancer has shown increasingly prominence and urgency. Interferon regulatory factor 3 （IRF3）， a member of the human interferon regulatory factor （IRF） family， serves as a crucial transcription factor. IRF3 plays a significant role in regulating the signal transduction process of the innate immune response. Recent research advancements have discovered IRF3’s pivotal role in the field of tumor immunology， particularly its significant impact on breast cancer. IRF3 regulates the growth and apoptosis of breast cancer cells and influences tumor cell behavior by inducing the production of type I interferons （IFN-I） and other critical cytokines. However， in breast cancer， the activation of IRF3 is suppressed by various mechanisms， including the obstruction of IRF3-dependent apoptosis pathways and the inhibition of stimulator of interferon genes （STING） expression through the modulation of microRNA expression. Under certain circumstances， IRF3 may also promote the occurrence and recurrence of breast cancer. This review comprehensively explores the fundamental characteristics of IRF3， its signaling pathways， roles in developing breast cancer， the latest research progress， and summarizes potential therapeutic strategies based on the mechanism of action of IRF3.
